GRAIL, Inc. (GRAL) Stock Analysis and Metrics

Grail

NASDAQ: GRAL

$71.87 ▼ -0.13 (-0.18%)

At close: Jul 13, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap2.77 Bn

P/E-7.00

P/S17.73

Div. Yield0.00

ROIC (Qtr)0.00

Revenue Growth (1y) (Qtr)28.11

Add ratio to table…

About

GRAIL is a healthcare company focused on early cancer detection through a blood based test called Galleri. The company develops and commercializes a multi cancer early detection screening tool that can detect a cancer signal shared by over fifty cancer types and predict the tissue of origin from a single blood draw. Galleri is intended to be used alongside existing single cancer screenings to increase the detection of cancers at an early stage when treatment is more likely to be curative.

GRAIL generates revenue primarily from the sale of its Galleri test to employers health systems payors digital health platforms and life insurance providers. The company also earns income from research use only offerings and collaborations with biopharmaceutical partners that apply its methylation technology to areas such as minimal residual disease monitoring and biomarker discovery. As of December 31 2025 GRAIL reported selling more than four hundred seventy five thousand commercial Galleri tests.

GRAIL holds a leading position in the emerging multi cancer early detection market. The company competes with firms such as Exact Sciences Corporation Guardant Health Inc and Natera Inc. GRAIL differentiates itself through its extensive clinical program which includes over three hundred eighty five thousand participants across multiple studies its broad intellectual property portfolio with hundreds of patents and its high capacity laboratory that is capable of processing up to one million tests per year. The company’s early mover status and partnerships with major health care institutions reinforce its market presence.

GRAIL serves a diverse set of customers that includes self insured employers large health systems such as the Mayo Clinic and the Cleveland Clinic digital health platforms payors and life insurance providers. The company also works with government programs like TRICARE and the United Kingdom’s National Health Service. Through these relationships GRAIL distributes its Galleri test to patients seeking early cancer screening.

Investment Thesis

▲ Bull case

GRAIL's NHS-Galleri trial results demonstrate clinically meaningful outcomes that are underappreciated by the market, particularly the fourfold increase in cancer detection rate when Galleri is added to standard of care screening and the 25% reduction in cancer diagnoses through emergency presentation, which directly translates to earlier intervention and potential curative treatment opportunities, signaling strong long-term adoption potential among providers seeking to improve patient outcomes and reduce costly late-stage presentations. The company's expanding EHR integration strategy, especially the Epic Aura platform targeting 450 health systems, represents a structural shift in accessibility that was not heavily promoted in the earnings call but could unlock significant volume growth by embedding Galleri ordering directly into physician workflows, reducing friction and accelerating adoption across large health systems that were previously hesitant due to administrative burden. Despite reporting 50% year-over-year test volume growth and 37% screening revenue growth, GRAIL maintained its 22%-32% annual revenue guidance range, indicating management is conservative about near-term execution risks; however, the pending ASCO data presentations for both NHS-Galleri and PATHFINDER 2 studies serve as imminent catalysts that could validate clinical utility and trigger upward revisions to guidance, especially if the data confirms sustained Stage IV reduction and early-stage detection benefits across broader populations. GRAIL's cash position of $823.1 million provides a multi-year runway to support growth initiatives without immediate financing pressure, allowing the company to continue expanding its sales force from 90 to 120 territories and deepen digital health partnerships with Function Health, Hims & Hers, and WHOOP, which are currently unquantified in guidance but represent high-potential channels for reaching asymptomatic, risk-appropriate populations outside traditional brick-and-mortar settings. The acceptance of GRAIL's final PMA submission by the FDA, based on data from over 25,000 PATHFINDER 2 participants and the NHS-Galleri prevalence screening round, removes a major regulatory hurdle and positions the company for potential market approval later in 2026 or early 2027, which would unlock broader reimbursement pathways and accelerate adoption in employer-sponsored and government-funded screening programs, a catalyst not fully priced into current expectations.

GRAIL's NHS-Galleri trial results demonstrate clinically meaningful outcomes that are underappreciated by the market, particularly the fourfold increase in cancer detection rate when Galleri is added to standard of care screening and the 25% reduction in cancer diagnoses through emergency presentation, which directly translates to earlier intervention and potential curative treatment opportunities, signaling strong long-term adoption potential among providers seeking to improve patient outcomes and reduce costly late-stage presentations. The company's expanding EHR integration strategy, especially the Epic Aura platform targeting 450 health systems, represents a structural shift in accessibility that was not heavily promoted in the earnings call but could unlock significant volume growth by embedding Galleri ordering directly into physician workflows, reducing friction and accelerating adoption across large health systems that were previously hesitant due to administrative burden. Despite reporting 50% year-over-year test volume growth and 37% screening revenue growth, GRAIL maintained its 22%-32% annual revenue guidance range, indicating management is conservative about near-term execution risks; however, the pending ASCO data presentations for both NHS-Galleri and PATHFINDER 2 studies serve as imminent catalysts that could validate clinical utility and trigger upward revisions to guidance, especially if the data confirms sustained Stage IV reduction and early-stage detection benefits across broader populations. GRAIL's cash position of $823.1 million provides a multi-year runway to support growth initiatives without immediate financing pressure, allowing the company to continue expanding its sales force from 90 to 120 territories and deepen digital health partnerships with Function Health, Hims & Hers, and WHOOP, which are currently unquantified in guidance but represent high-potential channels for reaching asymptomatic, risk-appropriate populations outside traditional brick-and-mortar settings. The acceptance of GRAIL's final PMA submission by the FDA, based on data from over 25,000 PATHFINDER 2 participants and the NHS-Galleri prevalence screening round, removes a major regulatory hurdle and positions the company for potential market approval later in 2026 or early 2027, which would unlock broader reimbursement pathways and accelerate adoption in employer-sponsored and government-funded screening programs, a catalyst not fully priced into current expectations.

▼ Bear case

GRAIL's NHS-Galleri trial failed to meet its primary endpoint of a statistically significant reduction in combined Stage III and IV cancer diagnoses, a critical flaw that raises doubts about the test's ability to deliver on its core population-level mortality reduction promise, and management's evasive answers during Q&A about oncologist feedback and the lack of clarity on whether the observed Stage IV reduction will persist or be offset by Stage III increases suggest underlying efficacy concerns that could limit long-term payer and provider adoption. The company's reliance on self-pay volume, which constitutes over two-thirds of Galleri tests sold, reveals a fragile business model vulnerable to economic downturns and consumer spending shifts, with management offering no concrete plan to increase reimbursement-driven volume from health systems or government programs, despite repeated emphasis on EHR integrations that have yet to yield measurable revenue contribution in the current quarter. Average selling price (ASP) decline, driven by channel mix shifts toward lower-priced digital health and employer partnerships, is eroding revenue growth momentum, and while management characterizes this as modest and mix-related, the persistent downward pressure on pricing without a clear path to volume-driven margin expansion threatens to keep adjusted EBITDA deeply negative, undermining the narrative of scalable profitability even as volumes rise. The sales force expansion from 90 to 120 territories, while framed as a growth driver, lacks detail on productivity timelines and territorial effectiveness, with management admitting most new hires won't be fully productive until midyear, raising execution risk that the expansion may not translate into proportional volume growth, especially if physician adoption remains concentrated in early adopter systems rather than scaling broadly across community practices. Despite highlighting partnerships with Function Health, Hims & Hers, Everlywell, and WHOOP, GRAIL provided no quantifiable financial impact from these digital health channels in its guidance, treating them as variables within an already wide 22%-32% revenue range, which suggests management lacks confidence in their near-term scalability and that these alliances may represent more marketing traction than sustainable revenue streams, leaving growth overly dependent on unpredictable consumer-facing channels.

GRAIL's NHS-Galleri trial failed to meet its primary endpoint of a statistically significant reduction in combined Stage III and IV cancer diagnoses, a critical flaw that raises doubts about the test's ability to deliver on its core population-level mortality reduction promise, and management's evasive answers during Q&A about oncologist feedback and the lack of clarity on whether the observed Stage IV reduction will persist or be offset by Stage III increases suggest underlying efficacy concerns that could limit long-term payer and provider adoption. The company's reliance on self-pay volume, which constitutes over two-thirds of Galleri tests sold, reveals a fragile business model vulnerable to economic downturns and consumer spending shifts, with management offering no concrete plan to increase reimbursement-driven volume from health systems or government programs, despite repeated emphasis on EHR integrations that have yet to yield measurable revenue contribution in the current quarter. Average selling price (ASP) decline, driven by channel mix shifts toward lower-priced digital health and employer partnerships, is eroding revenue growth momentum, and while management characterizes this as modest and mix-related, the persistent downward pressure on pricing without a clear path to volume-driven margin expansion threatens to keep adjusted EBITDA deeply negative, undermining the narrative of scalable profitability even as volumes rise. The sales force expansion from 90 to 120 territories, while framed as a growth driver, lacks detail on productivity timelines and territorial effectiveness, with management admitting most new hires won't be fully productive until midyear, raising execution risk that the expansion may not translate into proportional volume growth, especially if physician adoption remains concentrated in early adopter systems rather than scaling broadly across community practices. Despite highlighting partnerships with Function Health, Hims & Hers, Everlywell, and WHOOP, GRAIL provided no quantifiable financial impact from these digital health channels in its guidance, treating them as variables within an already wide 22%-32% revenue range, which suggests management lacks confidence in their near-term scalability and that these alliances may represent more marketing traction than sustainable revenue streams, leaving growth overly dependent on unpredictable consumer-facing channels.

Geographical Breakdown of Revenue (2025)

Peer Comparison

Companies in the Diagnostics & Research

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	WAT	Waters Corp /De/	31,055.11 Bn	69,126.88	8,236.16	4.86 Bn
2	TMO	Thermo Fisher Scientific Inc.	191.02 Bn	27.63	4.23	43.16 Bn
3	DHR	Danaher Corp /De/	137.16 Bn	37.32	5.54	18.48 Bn
4	IDXX	Idexx Laboratories Inc /De	42.82 Bn	39.09	9.63	0.83 Bn
5	NTRA	Natera, Inc.	39.09 Bn	-172.71	15.63	0.02 Bn
6	A	Agilent Technologies, Inc.	37.61 Bn	26.60	5.20	0.30 Bn
7	IQV	Iqvia Holdings Inc.	34.23 Bn	35.84	2.06	15.83 Bn
8	ILMN	Illumina, Inc.	28.14 Bn	32.98	6.40	1.49 Bn

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password